WO2007079146A8 - Treatment for non-hodgkin's lymphoma - Google Patents

Treatment for non-hodgkin's lymphoma

Info

Publication number
WO2007079146A8
WO2007079146A8 PCT/US2006/049431 US2006049431W WO2007079146A8 WO 2007079146 A8 WO2007079146 A8 WO 2007079146A8 US 2006049431 W US2006049431 W US 2006049431W WO 2007079146 A8 WO2007079146 A8 WO 2007079146A8
Authority
WO
WIPO (PCT)
Prior art keywords
hodgkin
lymphoma
treatment
ameliorate
symptom
Prior art date
Application number
PCT/US2006/049431
Other languages
French (fr)
Other versions
WO2007079146A1 (en
Inventor
Jeffrey S Miller
Carla Yunis
Original Assignee
3M Innovative Properties Co
Jeffrey S Miller
Carla Yunis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co, Jeffrey S Miller, Carla Yunis filed Critical 3M Innovative Properties Co
Publication of WO2007079146A1 publication Critical patent/WO2007079146A1/en
Publication of WO2007079146A8 publication Critical patent/WO2007079146A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a method of treating Non-Hodgkin's lymphoma. Generally, the method includes administering to a patient with Non-Hodgkin's lymphoma an amount of a TLR agonist compound effective to ameliorate at least one symptom or clinical sign of Non-Hodgkin's lymphoma.
PCT/US2006/049431 2005-12-28 2006-12-28 Treatment for non-hodgkin's lymphoma WO2007079146A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75442405P 2005-12-28 2005-12-28
US60/754,424 2005-12-28

Publications (2)

Publication Number Publication Date
WO2007079146A1 WO2007079146A1 (en) 2007-07-12
WO2007079146A8 true WO2007079146A8 (en) 2007-08-30

Family

ID=38228554

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/049431 WO2007079146A1 (en) 2005-12-28 2006-12-28 Treatment for non-hodgkin's lymphoma

Country Status (1)

Country Link
WO (1) WO2007079146A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106474143A (en) * 2015-08-26 2017-03-08 长春华普生物技术有限公司 Toll-like receptor TLR7 and TLR9 inhibition oligonucleotides are preparing for treating the application in terms of the medicine of B cell lymphoma

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06001669A (en) 2003-08-12 2006-04-28 3M Innovative Properties Co Oxime substituted imidazo-containing compounds.
US7897597B2 (en) 2003-08-27 2011-03-01 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
WO2005023190A2 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
BRPI0414856A (en) 2003-10-03 2006-11-21 3M Innovative Properties Co alkoxy-substituted imidazoquinolines
WO2005048933A2 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
US8598192B2 (en) 2003-11-14 2013-12-03 3M Innovative Properties Company Hydroxylamine substituted imidazoquinolines
NZ547467A (en) 2003-11-25 2010-06-25 3M Innovative Properties Co Substituted imidazo ring system and methods
US8802853B2 (en) 2003-12-29 2014-08-12 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
US8735421B2 (en) 2003-12-30 2014-05-27 3M Innovative Properties Company Imidazoquinolinyl sulfonamides
CA2559863A1 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
ES2392648T3 (en) 2004-12-30 2012-12-12 3M Innovative Properties Company Substituted chiral compounds containing a condensed 1,2-imidazo-4,5-c core
EP1831226B1 (en) 2004-12-30 2012-08-08 3M Innovative Properties Company Chiral tetracyclic compounds inducing interferon biosynthesis
JP2008530022A (en) 2005-02-04 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド Aqueous gel formulation containing immune response modifier
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032829A2 (en) * 2002-08-15 2004-04-22 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
EP1578419A4 (en) * 2002-12-30 2008-11-12 3M Innovative Properties Co Immunostimulatory combinations
EP1592302A4 (en) * 2003-02-13 2007-04-25 3M Innovative Properties Co Methods and compositions related to irm compounds and toll-like receptor 8

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106474143A (en) * 2015-08-26 2017-03-08 长春华普生物技术有限公司 Toll-like receptor TLR7 and TLR9 inhibition oligonucleotides are preparing for treating the application in terms of the medicine of B cell lymphoma

Also Published As

Publication number Publication date
WO2007079146A1 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
WO2007079146A8 (en) Treatment for non-hodgkin's lymphoma
WO2007079171A3 (en) Treatment for hodgkin's lymphoma
WO2007079202A3 (en) Treatment for acute lymhoblastic leukemia
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2007079169A3 (en) Treatment for acute myeloid leukemia
WO2006113942A3 (en) Method of inhibiting cathepsin activity
WO2006078463A3 (en) Method for treating cardiovascular disease
PL381247A1 (en) Heterocyclical condensed derivative, the medical composition containing it as well as its treatment application
WO2005027839A3 (en) Methods and reagents for the treatment of immunoinflammatory disorders
WO2007140002A3 (en) Method for treating non-hodgkin's lymphoma
WO2003057698A3 (en) Spiroazacyclic compounds as monoamine receptor modulators
WO2007137071A3 (en) Compositions of r(+) and s(-) pramipexole and methods of using the same
WO2005074607A3 (en) Method of treating hemolytic disease
WO2005094785A3 (en) Compositions capable of facilitating penetration across a biological barrier
AP2246A (en) Pesticidal composition and method for seed treatment.
WO2008011478A3 (en) Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2006138372A3 (en) Methods and reagents for the treatment of inflammatory disorders
AU2003229835A8 (en) Compounds, compositions and method for transporting cyclosporin molecules through the blood brain barrier
WO2005107771A3 (en) Composition comprising a survivin oligonucleotide and gemcitabine for the treatment of cancer
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
PL1694354T3 (en) Method for preventing and treating diabetes using neurturin
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2006121995A3 (en) Methods for treating nephrolithiasis
WO2006088786A3 (en) Compounds and uses thereof
EP1774029A4 (en) Method for detecting the risk of and for treatment of type 2 diabetes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06848245

Country of ref document: EP

Kind code of ref document: A1